TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37318885

Group type: EXPERIMENTAL
Intervention: Prematurely achieved cardiovascular risk (CVR)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Serum lipid ratios
Number of subjects: 218
Study: 37319109

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline DLQI mean scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline POEM mean scores
Number of subjects: 0
Study: 37319244

Group type: EXPERIMENTAL
Intervention: 10 mg modified-release prednisone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 100
Study: 37319250

Group type: EXPERIMENTAL
Intervention: Yima Nkqo peer support intervention
Number of subjects: 9
Study: 37319354

Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (3% to 7%)
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline
Number of subjects: 1318

Group type: COMPARATOR
Intervention: rhDNase
Number of subjects: 1318
Study: 37319432

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks for up to 8 cycles after ASCT.
Number of subjects: 21
Study: 37319435

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Second-course pembrolizumab
Number of subjects: 20
Study: 37319438

Group type: EXPERIMENTAL
Intervention: Oral Octreotide Capsules (OOC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Transitioning from injectable somatostatin receptor ligands (iSRLs) to Oral Octreotide Capsules (OOC)
Number of subjects: 58
Study: 37319437

Group type: EXPERIMENTAL
Intervention: Abatacept (IV) with a target trough of 10 μg/mL and higher Ctrough_1 (≥39 μg/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abatacept (IV) with Ctrough_1 <39 μg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abatacept (IV)
Number of subjects: 0
Study: 37320999

Group type: EXPERIMENTAL
Intervention: NT-proBNP level in patients without heart failure
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: NT-proBNP level in patients with heart failure
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: NT-proBNP cut-off value for ruling out heart failure
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curve for diagnosing heart failure
Number of subjects: 409
Study: 37321235

Group type: EXPERIMENTAL
Intervention: VLA1553
Number of subjects: 4128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4128
Study: 37321244

Group type: EXPERIMENTAL
Intervention: Reagents containing dextran sulfate (DS)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Reagents not containing dextran sulfate (DS)
Number of subjects: 165
Study: 37321280

Group type: EXPERIMENTAL
Intervention: High maternal EPDS and PSS scores
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: One-unit increment in maternal EPDS score
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: One-unit increment in maternal PSS score
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Combined high EPDS and PSS scores
Number of subjects: 536

Group type: COMPARATOR
Intervention: Adjustment for CHAOS score
Number of subjects: 536
Study: 37321368

Group type: EXPERIMENTAL
Intervention: Higher functional connectivity (FC) between dorsolateral prefrontal cortex and left frontoparietal and hippocampal areas
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Decreased functional connectivity (FC) between basal ganglia and right angular gyrus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Higher fractional anisotropy (FA) in the cingulum bundle and superior longitudinal fasciculus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cingulum bundle FA
Number of subjects: 48
Study: 37321625

Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 44
Study: 37321663

Group type: EXPERIMENTAL
Intervention: Intratumoral T4 immunotherapy (CAR-T cells)
Number of subjects: 40
Study: 37321665

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 11115
Study: 37321811

Group type: EXPERIMENTAL
Intervention: Surgical correction of pectus excavatum (PE)
Number of subjects: 44
Study: 37321955

Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 144

Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 144
Study: 37322010

Group type: EXPERIMENTAL
Intervention: MAOA variants (rs1137070, rs2064070, rs6323) and TPH2 variants (rs1386494, rs4570625)
Number of subjects: 0
Study: 37322121

Group type: EXPERIMENTAL
Intervention: Therapies matched to genomic alterations in 27 substudies
Number of subjects: 1593
Study: 37322274

Group type: EXPERIMENTAL
Intervention: IV-golimumab 2 mg/kg at week 0, week 4, then every 8 weeks
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo (crossover to IV-golimumab at week 16)
Number of subjects: 208
Study: 37322367

Group type: EXPERIMENTAL
Intervention: Sugemalimab plus chemotherapy (1,200 mg every 3 weeks)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 479
Study: 37322425

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 2710
Study: 37322482

Group type: EXPERIMENTAL
Intervention: Latozinemab (single infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S15JG (anti-sortilin antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latozinemab (in cynomolgus monkeys)
Number of subjects: 0
Study: 37322506

Group type: EXPERIMENTAL
Intervention: Standard care plus virtual assistant (chatbot)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study: 37322511

Group type: EXPERIMENTAL
Intervention: Bipolar haemostatic forceps (HemoStat/Pentax®) as experimental therapy (ET)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard therapy (ST) using haemoclip + / - epinephrine injection
Number of subjects: 90
Study: 37322521

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 890

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 890
Study: 37322537

Group type: EXPERIMENTAL
Intervention: Collastat® (collagen hemostatic matrix, CHM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Floseal® (gelatin hemostatic matrix, GHM)
Number of subjects: 160
Study: 37322538

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (3 g of probiotic preparation including eight bacterial strains)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (5 g of oat bran)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall study participation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Willingness to participate in a similar study
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Feasibility criteria
Number of subjects: 14
Study: 37322595

Group type: EXPERIMENTAL
Intervention: Early AMR treatment (more aggressive treatment with plasma exchange and monoclonal/polyclonal antibodies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late AMR treatment (less aggressive treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of early vs late AMR
Number of subjects: 0
Study: 37322836

Group type: EXPERIMENTAL
Intervention: CBT-I&N delivered before CPT
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CBT-I&N delivered after CPT
Number of subjects: 93

Group type: COMPARATOR
Intervention: CPT alone
Number of subjects: 93
Study: 37322842

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 37322892

Group type: EXPERIMENTAL
Intervention: Noninvasive Cardiac Output Monitoring (NICOM)
Number of subjects: 0
Study: 37323036

Group type: EXPERIMENTAL
Intervention: Telemonitoring follow-up
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard-care follow-up
Number of subjects: 217
Study: 37323051

Group type: EXPERIMENTAL
Intervention: RSV-targeted T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37323059

Group type: EXPERIMENTAL
Intervention: GSK2831781 450 mg intravenously (IV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: GSK2831781 450 mg IV
Number of subjects: 104
Study: 37323099

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg orally once a week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Denosumab and Alendronate
Number of subjects: 90
Study: 37323125

Group type: EXPERIMENTAL
Intervention: Spark (CBT-based mobile application)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active Control (psychoeducational mobile application)
Number of subjects: 60
Study: 37323509

Group type: EXPERIMENTAL
Intervention: Messaging on smoking-related COVID-19 risk and cessation support via instant messaging for three months (16 messages in total).
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Generic text messaging support for three months (16 messages).
Number of subjects: 1166
Study: 37323862

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 800

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 800
Study: 37323869

Group type: EXPERIMENTAL
Intervention: High-risk STS group
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Intermediate-risk STS group
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Low-risk STS group
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Asian population
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Non-Asian population
Number of subjects: 1412
Study: 37324125

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 258

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 258
Study: 37324410

Group type: EXPERIMENTAL
Intervention: Afterload-related cardiac performance (ACP)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Expected cardiac output-systemic vascular resistance (CO-SVR) curve model
Number of subjects: 290
Study: 37324622

Group type: EXPERIMENTAL
Intervention: MEDI-app (smartphone app with alarm for drug intake, visual confirmation of drug administration, medication intake history)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Usual care (conventional treatment)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: MEDI-app
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1042
Study: 37324629

Group type: EXPERIMENTAL
Intervention: Women with ARD history
Number of subjects: 207

Group type: COMPARATOR
Intervention: Women without ARD history
Number of subjects: 207
Study: 37325226

Group type: EXPERIMENTAL
Intervention: Enhanced External Counter Pulsation (EECP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37325351

Group type: EXPERIMENTAL
Intervention: Health care-associated primary bloodstream infections (BSIs)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Corrected gestational age <28 weeks at infection
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Fetal growth restriction (FGR)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Proven pathogen-related BSIs
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: One positive blood culture
Number of subjects: 494
Study: 37325398

Group type: EXPERIMENTAL
Intervention: Short-term low-saturated fat diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-saturated fat diet
Number of subjects: 0
Study: 37325545

Group type: EXPERIMENTAL
Intervention: Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A-IADL-Q and ADCS-ADL
Number of subjects: 0
Study: 37325628

Group type: EXPERIMENTAL
Intervention: In-stent restenosis (ISR) patients
Number of subjects: 60
Study: 37325662

Group type: EXPERIMENTAL
Intervention: CoronaVac
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (23-valent pneumococcal polysaccharide vaccine and inactivated hepatitis A vaccine)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control
Number of subjects: 270
Study: 37325860

Group type: EXPERIMENTAL
Intervention: afamitresgene autoleucel (afami-cel) therapy after low-dose radiotherapy (LDRT) at 5.6 Gy/4 fractions to the liver
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: low-dose radiotherapy (LDRT)
Number of subjects: 1
Study: 37325931

Group type: EXPERIMENTAL
Intervention: Breast Conservation Surgery (BCS)
Number of subjects: 1462

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Triple-negative receptor subtype
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Residual Cancer Burden (RCB) class
Number of subjects: 1462
Study: 37326265

Group type: EXPERIMENTAL
Intervention: Emotional support strategies, such as counselling and emergency preparedness training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study: 37326325

Group type: EXPERIMENTAL
Intervention: Video laryngoscope
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 1417
Study: 37326322

Group type: EXPERIMENTAL
Intervention: Testosterone gel (1.62% daily, adjusted to maintain testosterone levels between 350 and 750 ng/dL)
Number of subjects: 5246

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 5246

Group type: EXPERIMENTAL
Intervention: Testosterone gel (1.62% daily)
Number of subjects: 5246
Study: 37326371

Group type: EXPERIMENTAL
Intervention: Total transfemoral access (TFA)
Number of subjects: 68
Study: 37326473

Group type: EXPERIMENTAL
Intervention: Continuous administration of meropenem
Number of subjects: 607

Group type: COMPARATOR
Intervention: Intermittent administration of meropenem
Number of subjects: 607
Study: 37326562

Group type: EXPERIMENTAL
Intervention: Perimenstrual phase
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Midluteal phase
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Midfollicular phase
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cycle phase predictors
Number of subjects: 38
Study: 37326645

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 367

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 367
Study: 37326674

Group type: EXPERIMENTAL
Intervention: Fibromyalgia (FM) group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fibromyalgia (FM) group (high-affinity binders)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 15
Study: 37326678

Group type: EXPERIMENTAL
Intervention: Juvenile fibromyalgia (JFM) group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy adolescent girls (control group)
Number of subjects: 66
Study: 37326854

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg IV
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 17
Study: 37326942

Group type: EXPERIMENTAL
Intervention: SHR2285 (25-600 mg single ascending doses)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: SHR2285 (100-400 mg multiple ascending doses)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 37327026

Group type: EXPERIMENTAL
Intervention: VR-based Joviality positive psychological intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham VR (2D wildlife footage and nature-based settings with inert music)
Number of subjects: 84
Study: 37327046

Group type: EXPERIMENTAL
Intervention: Self-reported vaccination status (index test)
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Self-reported vaccination status at telephone follow-up
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Self-reported vaccination status at index ED visit
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Self-reported number of doses
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Self-reported brand of the first dose
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Self-reported brand of the second dose
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Self-reported brand of the third dose
Number of subjects: 1361
Study: 37327113

Group type: EXPERIMENTAL
Intervention: Romidepsin 10 mg/m2 IV on days 1, 8, and 15 plus lenalidomide 25 mg orally from days 1 to 21 of a 28-day cycle for up to 1 year
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Romidepsin plus lenalidomide
Number of subjects: 29
Study: 37327216

Group type: EXPERIMENTAL
Intervention: Female healthcare workers
Number of subjects: 4165

Group type: COMPARATOR
Intervention: Male healthcare workers
Number of subjects: 4165

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 4165

Group type: EXPERIMENTAL
Intervention: Healthcare workers expressing ITL
Number of subjects: 4165
Study: 37327230

Group type: EXPERIMENTAL
Intervention: Humanoid robot Pepper used at home by children with cochlear implants and their families for 1 month.
Number of subjects: 10
Study: 37327319

Group type: EXPERIMENTAL
Intervention: Bavituximab
Number of subjects: 33
Study: 37327369

Group type: EXPERIMENTAL
Intervention: Topical Azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral Doxycycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37327372

Group type: EXPERIMENTAL
Intervention: Cervical cancer screening education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 37327382

Group type: EXPERIMENTAL
Intervention: Active warming
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Passive warming
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 37327461

Group type: EXPERIMENTAL
Intervention: Dato-DXd 6 mg/kg once every 3 weeks
Number of subjects: 210
Study: 37327468

Group type: EXPERIMENTAL
Intervention: Adagrasib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37327527

Group type: EXPERIMENTAL
Intervention: Apixaban (therapeutic doses)
Number of subjects: 298
Study: 37327673

Group type: EXPERIMENTAL
Intervention: Subphenotype 1
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Subphenotype 2
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Subphenotype 3
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Subphenotype 4
Number of subjects: 382
Study: 37327677

Group type: EXPERIMENTAL
Intervention: emtricitabine-tenofovir disoproxil fumarate (F/TDF) or emtricitabine-tenofovir alafenamide (F/TAF) given as a double dose once either 5 or 21 hours before ex vivo HIV-challenge.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 144
Study: 37327809

Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 1 day
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 2 days
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 3 days
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ganaplacide 800 mg plus lumefantrine-SDF 960 mg for 1 day
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ganaplacide 200 mg plus lumefantrine-SDF 480 mg for 3 days
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 480 mg for 3 days
Number of subjects: 512

Group type: COMPARATOR
Intervention: Artemether plus lumefantrine for 3 days (control)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg once daily for 3 days in children
Number of subjects: 512

Group type: COMPARATOR
Intervention: Artemether plus lumefantrine for 3 days (control in children)
Number of subjects: 512
Study: 37327883

Group type: EXPERIMENTAL
Intervention: National Early Warning Score 2 (NEWS2) with cutoff ≥5
Number of subjects: 848

Group type: COMPARATOR
Intervention: Bova score with cutoff >4
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: National Early Warning Score 2 (NEWS2)
Number of subjects: 848
Study: 37327955

Group type: EXPERIMENTAL
Intervention: Data-driven HRF estimation approach
Number of subjects: 0
Study: 37327980

Group type: EXPERIMENTAL
Intervention: Coronary plaque rupture (PR)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Coronary plaque erosion (PE)
Number of subjects: 297
Study: 37328176

Group type: EXPERIMENTAL
Intervention: Standardised breathing advice guided by visual biofeedback from the laryngoscope video screen after EILO diagnosis verification.
Number of subjects: 120
Study: 37328178

Group type: EXPERIMENTAL
Intervention: Nature-based walking intervention (50 minutes, three times per week for 12 weeks)
Number of subjects: 20
Study: 37328287

Group type: EXPERIMENTAL
Intervention: Anti-IL-6R therapy (tocilizumab or sarilumab)
Number of subjects: 92
Study: 37328392

Group type: EXPERIMENTAL
Intervention: Biolimus A9™ drug coated balloon (BA9-DCB)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Paclitaxel-coated SeQuent® Please DCB
Number of subjects: 201
Study: 37328522

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 152

Group type: COMPARATOR
Intervention: IV ceftriaxone
Number of subjects: 152
Study: 37328712

Group type: EXPERIMENTAL
Intervention: Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control subjects (n = 12)
Number of subjects: 36
Study: 37328731

Group type: EXPERIMENTAL
Intervention: Safe Delivery Application (SDA) installed on smartphones, with half a day of introduction to the app.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 176
Study: 37328736

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924

Group type: EXPERIMENTAL
Intervention: Alirocumab (LDL-C < 25 mg/dL)
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo (LDL-C < 25 mg/dL)
Number of subjects: 18924

Group type: EXPERIMENTAL
Intervention: Alirocumab (LDL-C < 15 mg/dL)
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo (LDL-C < 15 mg/dL)
Number of subjects: 18924